Educational Resources

This strategy report outlines five actionable priorities to improve bladder cancer care across health systems. It also focuses on patient education, care coordination, referral pathways, provider knowledge, and program measurement. The report addresses the challenges posed by high recurrence rates, complex patient populations, and evolving therapies, highlighting the need for standardized, guideline-concordant care. Published - April 2026

Posted on 01/15/2026

View the full publication:

View the Plain Language Summary of the publication

© Johnson & Johnson and its affiliates 2025. 12/25 CP-557697v1

Posted on 11/12/2025

In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.

Posted on 11/12/2025

A patient and caregiver website to learn more and find resources about each step of the CAR T cell therapy journey. Visit www.explorecelltherapy.com or download the resource below to learn more.

Posted on 11/12/2025

The Inflation Reduction Act of 2022 included several provisions to reduce OOP costs for Medicare Part D medicines:¹-3

In 2026, $2,100 is the total maximum OOP cost patients will pay for their covered Part D drugs. This includes their annual deductible.

Patients have the option to spread their OOP costs out over the course of the year by opting in to the Medicare Prescription Payment Plan.

Posted on 11/12/2025

In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.

Posted on 11/6/2025

To view the full publication, please refer to San-Miguel, J, et al. N Engl J Med. 2023;389(4):335-347 or click the resource below to view the Plain Language Summary of Publication of this article.

Posted on 10/29/2025

MyHealthcareFinances is a freely available website to help patients and caregivers understand finances related to healthcare and steps that may lower costs. The site is a collaboration between Pfizer and Triage Cancer, joining people with a shared passion for improving healthcare-related financial literacy. Visit https://www.myhealthcarefinances.com/ for more information.

Posted on 10/29/2025

Live: Call 1-877-744-5675 (Monday–Friday 8 AM–8 PM ET)

Online: Visit http://PfizerOncologyTogether.com

Pfizer is committed to supporting patients throughout their treatment journey. With Pfizer Oncology Together, patients prescribed a Pfizer Oncology medication can get help identifying financial assistance options and be connected to resources that may help with some of their day-to-day challenges.

Pfizer Oncology Together can help healthcare providers by:

Assisting with benefits verification, prior authorizations, appeals, billing and coding, and specialty pharmacy coordination

Connecting them and their office staff to a Pfizer Field Reimbursement Manager (FRD) who can help address specific access and reimbursement issues—in person or over the phone

Offering and assisting with online portals that provide registered users with access and financial assistance resources

Pfizer Oncology Together can help patients by:

Connecting them with financial assistance resources—regardless of their insurance coverage

Providing personalized support from a Pfizer Oncology FRM who can help identify resources and organizations that may provide additional assistance

Please visit http://PfizerOncologyTogether.com for more details, or contact your local FRM or AP&R Director to learn more.

© 2024 Pfizer Inc. All rights reserved. PP-UNP-USA-4653 September 2024

Posted on 05/14/2025

Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine therapy in participants with node-positive ER+/HER2- early breast cancer with high risk of recurrence. The main purpose of this study is to compare the Invasive Breast Cancer-Free Survival (IBCFS) over a period of up to 5 years. 4220 participants will be included in this study around the world. Participants will have equal chance to be assigned to receive either of the treatment combinations.